Loading stockRelated stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockRelated stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | APR 2026 ~7.4:1 split | APR 2025 6:1 split | APR 2024 | APR 2023 | APR 2022 |
|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | $0 | $0 |
| General & Administrative | $5 | $3 | $3 | $7 | $7 |
| Research & Development | $4 | $1 | $6 | $7 | $5 |
| Total Operating Expenses | $9 | $4 | $10 | $15 | $12 |
| Operating Income | -$9 | -$4 | -$10 | -$15 | -$12 |
| Non-Operating | |||||
| Net Interest Expense | -$0 | -$0 | -$0 | -$0 | -$0 |
| Other Non-Operating Income (Expense) | $0 | $0 | $0 | $0 | $0 |
| EBT (Earnings Before Tax) | -$9 | -$5 | -$10 | -$15 | -$12 |
| Income Tax Expense | $0 | — | — | — | — |
| Net Income | |||||
| Net Income | -$9 | -$5 | -$10 | -$15 | -$12 |
| EPS (Basic) | -$2.63 | -$11.32 | -$132.33 | -$206.01 | -$189.00 |
| EPS (Diluted) | -$2.63 | -$11.32 | -$132.33 | -$206.01 | -$189.00 |
| Weighted Avg Shares (Basic) | 3.3M | 450,799 | 676,565 | 97.5M | 89.1M |
| Weighted Avg Shares (Diluted) | 3.3M | 450,799 | 676,565 | 97.5M | 89.1M |
| Shares Outstanding | 3.3M | 450,799 | 75,173.889 | 72,236.308 | 65,996.499 |
Alzamend Neuro (ALZN) generated about n/a in revenue and -$9 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Alzamend Neuro reported about -$9 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 10 Sept 2026, covering the period ending 31 Jul 2026, as reported to the SEC. Data last refreshed 11 Sept 2026. How this is calculated.
Fiscal year ends Apr.